Artikel

ADOPT study milestones

The important milestones achieved in the ADOPT study

It was our pleasure to meet Prof. Carolyn Lam from the National Heart Centre, Singapore, and discuss this significant study to learn how it is moving forward.

ADOPT (Asian Diabetes Outcomes Prevention Trial) is a prospective, multinational randomized open-label study conducted in Asia Pacific (Taiwan, China, India, Malaysia, and Singapore) aiming to include 2,400 adults with type 2 diabetes without known cardiovascular disease.

This trial is investigating whether intensive preventive therapy (high dose renin-angiotensin-aldosterone system inhibitors, beta-blockade, sodium-glucose co-transporter 2 inhibitors) among biomarker (NT-proBNP) identified high-risk type 2 diabetes patients without pre-existing cardiovascular disease, may be associated with reduced cardiovascular events compared to standard of care.

Key facts
  • Prof. Carolyn Lam discusses the ADOPT study (Asian Diabetes Outcomes Prevention Trial).
  • ADOPT is a prospective, randomized study conducted in Asia Pacific for adults with type 2 diabetes without known cardiovascular diseases.
  • ADOPT study aims to investigate whether an intensive preventive therapy in high risk type 2 diabetes patients is associated with reduced cardiovascular events compared to standard of care.
  • The first patient enrollment happened in August 2020.
  • The biggest challenges faced during this study involved logistics of cross-country collaboration and covid-19 and these were overcome with strong teamwork and the motivation to always put the patient first.